LLY241004C570000
- 311.40
- 0.000.00%
Eli Lilly and Co Newsroom
Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,150
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,150
Deutsche Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Eli Lilly Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Eli Lilly, Maintains $885 Price Target
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
JPMorgan raises the target price of Eli Lilly and Co to $1100
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,101
Correction: JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1100. Action Price Target Changed to Raises
Eli Lilly Is Maintained at Overweight by JP Morgan
Bullish on the future of the "weight-loss miracle drug" Tesofensine, Citigroup reinitiates coverage of eli lilly and co (LLY.US) with a "buy" rating.
Eli Lilly Analyst Ratings
Citigroup Reinstates Buy on Eli Lilly, Announces $1060 Price Target
BofA Securities Initiates Eli Lilly and Co(LLY.US) With Buy Rating
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,100